Your session is about to expire
← Back to Search
MAD Cohorts 1 to 4: Participants receiving ECC5004 for Type 2 Diabetes
Study Summary
This trial is testing a new drug to help treat Type 2 Diabetes in healthy & diabetic participants. It's a safe & controlled study.
- Type 2 Diabetes
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Logistics
Participation is compensated
You will be compensated for participating in this trial.
Who is running the clinical trial?
Media Library
- You are not currently receiving any medical treatment.You weigh between 110 and 265 pounds and have a body mass index (BMI) between 24 and 40.Your body mass index (BMI) falls between 18 and 32 kilograms per square meter.You have no major health problems in your physical exam, ECG, vital signs, lab tests, medical, or psychiatric history.
- Group 1: MAD Cohorts 1 to 4: Participants receiving ECC5004
- Group 2: MAD Cohorts 1 to 4: Participants receiving Placebo
- Group 3: SAD Cohorts 1 to 2: Participants receiving ECC5004
- Group 4: SAD Cohorts 1 to 2: Participants receiving Placebo
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is the age range for this medical experiment limited to those over 25?
"This research study is open to individuals between the ages of 18 and 70. Additionally, there are 195 studies available for those under eighteen years old and 1,124 trials designed with seniors above 65 in mind."
Are enrollees currently being accepted to participate in this clinical experiment?
"Per clinicaltrials.gov, this trial is actively recruiting patients with the original post date being December 1st 2022 and a subsequent edit on December 8th 2022."
How many people are currently participating in this clinical experiment?
"Affirmative. According to the clinicaltrials.gov listing, this medical trial has been actively seeking participants since December 1st 2022 and is currently recruiting 64 patients from one location."
Has the FDA granted authorization for Cohorts 1 to 2 participants to receive ECC5004 as a treatment for SAD?
"SAD Cohorts 1 to 2: Participants receiving ECC5004 received a score of 1, as Phase 1 trials typically indicate limited data regarding safety and efficacy."
Are there any restrictions to joining this clinical trial?
"This clinical study is seeking 64 volunteers, aged 18-70 years old, who are diagnosed with type 2 diabetes mellitus. Additional criteria include a BMI of 18.0 - 32.0 kg/m2 and hemoglobin A1c ≤ 6.0% for all participants and postmenopausal status (or accepted true abstinence) in female patients as well as contraception use or abstention from intercourse in male applicants. Furthermore, physical examinations must be within normal parameters as indicated by vital sign measurements, ECG readings, laboratory tests results, medical history assessments and psychiatric evaluations; eligible candidates must also demonstrate the capacity to comprehend an informed consent document"
Share this study with friends
Copy Link
Messenger